CSIMarket Company Name, Ticker, Customers, else..
 
Erytech Pharma S a   (NASDAQ: ERYP)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 23
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Erytech Pharma S A
Erytech Pharma S.A. is a biopharmaceutical company that focuses on developing therapeutic treatments for rare forms of cancer and orphan diseases. The company utilizes its proprietary technology platform, which involves encapsulating drugs in red blood cells, to create innovative therapies. Erytech Pharma's goal is to improve the lives of patients by delivering therapeutics that offer significant benefits over existing treatments.


   Company Address: 60 Avenue Rockefeller Lyon 69008
   Company Phone Number: 4 78 74 44 38   Stock Exchange / Ticker: NASDAQ ERYP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BLRX        6.23% 
IMRX        10.53% 
• View Complete Report
   



Mink Therapeutics Inc

The Biotechnology and Pharmaceuticals company published operating deficit of $-2.502678 million, in the most recent fiscal period

Trailing the large companies in the Biotechnology and Pharmaceuticals sector, a few smaller corporations are reporting the results. Mink Therapeutics Inc said it has reported operating deficit of $-2.502678 million, for the fourth quarter of 2024.

Inhibrx Biosciences Inc

Extremely demanding reporting season for INBX all along the fiscal fourth quarter of 2024

INBX announced disastrous Dec 31 2024 report, where Revenue faded by -93.88 % to $0.10 million and net deficit per share has extended to $-3.27, from the similar reporting season a year prior.

Zeo Scientifix Inc

The Losses have widen more at the Zeo Scientifix Inc in November to January 31 2025 financial interval

For the November to January 31 2025 financial interval BPSR increased a loss per share of $-0.20 per share compare to $-0.17 a year ago and grew loss from $-0.19 per share from the previous reporting season. The revenue decreased by -5.546 % to $1.09 million from $1.15 million in the corresponding reporting season a year ago and sequentially Revenue deteriorated by -12.379 % from $1.24 million.

Pharmacyte Biotech Inc

In the November to January 31 2025 financial period operating shortfall embodied enhancement to $-1.868946 million, at the PMCB

As the earnings season of the November to January 31 2025 goes on, countless companies have reported their results. Some of them, are various corporations in the Biotechnology and Pharmaceuticals industry. And today, Pharmacyte Biotech Inc published operating shortfall of $-0.960252 million, for the most recent fiscal period.

Sangamo Therapeutics Inc

Breathtaking numbers, by the company over the fourth quarter of 2024

company announced very solid Revenue elevation of 269.785 % year on year to $7.55 million in the fourth quarter of 2024, but lost money at $-0.09. Sangamo Therapeutics Inc s' performance comes for many as a new revelation, as the company's presents top-line gain while remainder of Biotechnology and Pharmaceuticals sectors realizes -2.69% contraction in revenue.










Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com